Jan Lindeman, M.Sc. MBA (CEO) has a diverse background in the technology sector. Before joining DDL, he was managing director of a datacenter and cloud service provider, and held commercial leadership roles at Microsoft. Jan has a Master’s degree in applied physics from Delft University of Technology and an MBA from University of Bradford, School of Management.
Leen-Jan van Doorn, Ph.D. (CBO) is responsible for Business Development and one of the founders of DDL. He received his Ph.D. in molecular virology from the Erasmus University of Rotterdam, the Netherlands. He has specialized in molecular typing of infectious organisms such as hepatitis B and C, human papillomavirus and respiratory viruses. Dr. van Doorn has published more than 180 papers in international scientific journals as well as various book chapters.
Anco Molijn, M.Sc. (CTO) has extensive experience in the fields of molecular biology, virology and molecular pathology. Before joining DDL in 1998, he worked at the department of pathology of the Erasmus University of Rotterdam and St. Judes Childrens hospital (Memphis, USA).
Ingrid Kolenbrander, CPA (CFO) is a chartered accountant from the University of Amsterdam. Ingrid worked as senior manager for KPMG and was Finance Director at Schoevers.
Wim Quint, Ph.D. is one of the founders of DDL and is now president of the Advisory Board. He received his Ph.D. in molecular virology from the University of Nijmegen, the Netherlands. He has specialized in molecular diagnostics of infectious diseases and is a key opinion leader on molecular studies of human papillomavirus. Dr. Quint has published more than 400 papers on various topics in international scientific journals.